

A patient with chest pain and ST-elevation in aVR and ST depression in all other leads

ACCA Masterclass 2017

Sofie Gevaert







Mr LP, 55-years-old



History:

Hypertension, treated with Perindopril 5mg and Nebivolol 5mg

Current:

- 01.00 am: progressive severe thoracic pain radiating to left arm
- Orthopnoea
- 112→Medical emergency team

Other CV risk factors:

- Hyperlipidaemia
- Obesity
- Sudden death of father at 50 y





ARE THE ESC

MET 08.00 am: parameters, clinical exam


- BP 142/72 mmHg, HR 160 bpm, regular, SaO_2 88%, Resp R 27/min
- Clammy, cold extremities
- No jugular distension
- No cardiac murmur
- Bilateral crepitations
- No peripheral edema





FMC in patient with chest pain

















WE ARE THE ESC

1. ER: Patient with chest pain, 08.28 am



Further strategy?

WE ARE THE ESC

- Further stabilisation, diagnostics in ER?
- Direct transfer to cathlab?





2. ER: dyspnoea, orthopnoea



50% have ≥2 diagnoses, which may result in acute respiratory failure*!

Basic measures

- BP, HR, respiratory rate, SpO₂ & temperature
- Start oxygen to target SpO₂ 94-98%
- Start i.v. line & monitor patient

Criteria for transfer to ICU

(despite treatment for 30 minutes)

- Respiratory rate >35/min
- SBP <90 mmHg

• SpO₂ <85%

HR > 120 bpm

- Investigations:
- ECG

Chest X-ray

BNP

Venous BG


- Blood count
- Tn
- D-dimers if suspicion of PE





WE ARE THE ESC

Chest X-ray 08.32 am




Furosemide 40mg IV (MET)






Quick look echo







Clinical condition defined as the inability of the heart to deliver an adequate amount of blood to the tissues to meet resting metabolic demands as a result of impairment of its pumping function.







CONGESTION

Н 0 P Ε R U S

WARM-WET WARM-DRY COLD-DRY **COLD-WET**

ESC guidelines AHF 2015





MERGENCY DEPAR	5 min
¥ III	15 min
	60 min

0 min

EARLY TRIAGE & MONITORING Start high flow O2

Establish i.v. access

- Age: 65–74, ≥75
- Heart rate > 100 beats per minute Systolic blood pressure < 100 mmHg
- Proportional pulse pressure ≤25 % (Cl <2.2l/min/m²)
- Orthopnea (PCWP >22 mmHg) Tachypnea (>20/min), >30/min (!)
- Killip class II-IV
- Clinical symptoms of tissue hypoperfusion/hypoxia:
 - cool extremities. decreased urine output (urine output <40 ml/h) - decreased capillary refill or mottling - alteration in mental status
- CORRECT: hypoglycemia & hypocalcemia,

• TREAT: sustaned arrhythmias: brady- or tachy-

INITIAL RESUSCITATION Arterial and a central venous

- catheterization with a catheter capable of measuring central venous oxygen saturation Standard transthoracic echocardiogram
- to assess left (and right) ventricular function and for the detection of potential mechanical complications following MI
- · Early coronary angiography in specialized myocardial intervention center when signs and/or symptoms of ongoing myocardial ischemia (e.g. ST segment elevation

- over a 30-minute period to achieve a central venous pressure of 8 to 12 mmHg or until perfusion improves (with a maximum of 500 ml) CONSIDER NIVmechanical ventilation for comfort (fatigue, distress) or as needed:
- To correct acidosis - To correct hypoxemia INOTROPIC SUPPORT (dobutamine and/or vasopressor support)

Isotonic saline-fluid challenge of 20 to 30 ml per kilogram of body weight

TREATMENT GOALS

- a mean arterial pressure of 60 mmHg or above,
- a mean pulmonary artery wedge pressure of 18 mmHg or below,
- a central venous pressure of 8 to 12 mmHg,
- a urinary ouput of 0,5 ml or more per hour per kilogram of body weight
- an arterial pH of 7.3 to 7.5 a central venous saturation (ScvO₂) ≥70% (provided SpO₂ ≥93% and Hb level ≥9 g/dl)

In persistent drug-resistant cardiogenic shock, consider mechanical circulatory support

myocardial infarction).

08.45 am



- Ongoing chest pain despite high dose opioids
- SaO₂ 90 despite FiO₂ 90%
- Persisting respiratory failure despite initial measures
- Troponin T 435 ng/L, creatinine 2.1 mg/dL (CKD-EPI 30 mL/min), Hct 42%
- PH 7.24, PCO₂ 47mmHg, lactate 34.1 mg/dL (<11.3 mg/dL, =3.8mmol/L)





Invasive strategy: Timing, antithrombotic R/ and access

WE ARE THE ESC

- Timing?
- Antiplatelet?
 - None
 - ASA mono
 - DAPT
- Anticoagulation?
 - None
 - UFH
 - LMWH
 - Fondaparinux
 - Bivalirudin
- Access?





Timing



Very-high-risk criteria

- Haemodynamic instability or cardiogenic shock
- Recurrent or ongoing chest pain refractory to medical treatment
- · Life-threatening arrhythmias or cardiac arrest
- Mechanical complications of MI
- Acute heart failure


Immediate Invasive

(<2 hr)

rrent dynamic ST-T wave changes, particularly with intermittent ST-elevation







Cardiovascular Care Association

ACCA

SOCIETY OF


Ischemic risk



TIMI Risk Score Calculator for UA/NSTEMI Age ≥ 65 years? ☐ Yes (+1) ≥ 3 Risk Factors for CAD? ☐ Yes (+1) Known CAD (stenosis $\geq 50\%$)? ☐ Yes (+1) ASA Use in Past 7d? ☐ Yes (+1) Severe angina (≥ 2 episodes w/in 24 hrs)? Yes (+1) ST changes \geq 0.5mm? ✓ Yes (+1) + Cardiac Marker? Yes (+1) Score: 3 points What does this score mean? 13% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.







www.crusadebleedingscore.org





High ischemic and high bleeding risk KD and shock state

UFH 5000 IU bolus ASA 200mg IV

It is recommended to assess kidney function by eGFR in all patients.	1	С
It is recommended to administer the same first-line antithrombotic treatment as in patients with normal kidney function, with appropriate dose adjustment if indicated.	1	В
Depending on the degree of renal dysfunction, it is recommended to switch parenteral anticoagulation to UFH or to adjust the doses of fondaparinux, enoxaparin and bivalirudin, as well as the dose of small molecule GPIIb/IIIa inhibitors.	-	В
It is recommended to switch s.c. or iv. anticoagulation to UFH infusion adjusted to the aPTT when eGFR is <30 mL/min/ 1.73 m ² (for fondaparinux, when eGFR is	-	n


anticoagulation.

Oral antiplatelet therapy Aspirin is recommended for all patients without contraindications at an initial oral loading dose^d of 150-300 mg (in aspirin-naive patients) and a maintenance dose of 75-100 mg/ day long-term regardless of treatment strategy. A P2Y₁₂ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risk of bleeds. Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindications.e for all patients at moderate-to-high risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication.e • Clopidogrel (300-600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral

ESC guidelines NSTE-ACS 2015

ACCA Masterclass 2017

Coronary angiography 09.20 am



Shock, peripheral VC: Femoral access

CT angiography 09.50 am









Imaging		
TTE is recommended as an	ed as an	
Initial imaging investigation.		
In unstabled patients with a		
suspicion of AAS, the following		
Imaging modalities are		
recommended according to		
local availability and expertise:		
TOE	I	U
• CT		С

ESC guidelines Aortic dis. 2014

Type A dissection with dissection left main



- Urgent surgery
 - Tear ascending aorta
 - Urgent surgery:Hemiarch
 Sinotubular junction → proximal arch
 - Postoperative: stroke, AKI
 - Rehab program







ACCA Masterclass 2017

Sofie Gevaert







WE ARE THE ESC